Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN

Vaccine

Volumn 29, Issue 8, 2011, Pages 1657-1665

  Mallick, Amirul Islam ^a   Parvizi, Payvand ^a   Read, Leah R ^a   Nagy, Éva ^a   Behboudi, Shahriar ^b   Sharif, Shayan ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Chicken; CpG ODN; H4N6; Immune response; Influenza virus; Interferon gamma; Virosomes

Indexed keywords

AVIAN INFLUENZA VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT GAMMA INTERFERON; VIROSOME VACCINE;

ANIMAL EXPERIMENT; ARTICLE; AVIAN INFLUENZA; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; CELL PROLIFERATION; CHICKEN; CONTROLLED STUDY; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

EID: 79952708969     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.046     Document Type: Article

References (54)

1. Senne DA, Panigrahy B, Kawaoka Y, Pearson JE, Suss J, Lipkind M, et al. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 1996;40(2):425-37.
2. Suarez DL. Evolution of avian influenza viruses. Vet Microbiol 2000;74(1-2):15-27.
3. Bagai S, Sarkar DP. Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells. Biochim Biophys Acta 1993;1152(1):15-25.
4. Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, Palache AM, et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 2003;21(9-10):925-31.
5. Gluck R, Metcalfe IC. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine 2003;21(7-8):611-5.
6. Stegmann T, Morselt HW, Scholma J, Wilschut J. Fusion of influenza virus in an intracellular acidic compartment measured by fluorescence dequenching. Biochim Biophys Acta 1987;904(1):165-70.
7. Wilschut J. Influenza vaccines: the virosome concept. Immunol Lett 2009;122(2):118-21.
8. Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 1975;2(7941):899-901.
9. Bron R, Ortiz A, Dijkstra J, Stegmann T, Wilschut J. Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol 1993;220:313-31.
10. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz Jr SJ. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994;344(8916):160-3.
11. Bungener L, Huckriede A,Wilschut J, Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci Rep 2002;22(2):323-38.
12. Grimaldi S, Giuliani A, Giuliani A, Ferroni L, Lisi A, Santoro N, et al. Engineered liposomes and virosomes for delivery of macromolecules. Res Virol 1995;146(4):289-93.
13. Kawano H, Mifune K, Ohuchi M,Mannen K, Cho S, Hiramatsu K, etal. Protection against rabies in mice by a cytotoxic T cell clone recognizing the glycoprotein of rabies virus. J Gen Virol 1990;71(Pt 2):281-7.
14. Kapczynski DR, Tumpey TM. Development of a virosome vaccine for Newcastle disease virus. Avian Dis 2003;47(3):578-87.
15. Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008;7(8):1141-50.
16. Kohl S, Lawman MJ, Rouse BT, Cahall DL. Effect of herpes simplex virus infection on murine antibody-dependent cellular cytotoxicity and natural killer cytotoxicity. Infect Immun 1981;31(2):704-11.
17. Ponimaskin E, Bareesel KK, Markgraf K, Reszka R, Lehmann K, Gelderblom HR, et al. Sendai virosomes revisited: reconstitution with exogenous lipids leads to potent vehicles for gene transfer. Virology 2000;269(2):391-403.
18. Bonnafous P, Stegmann T. Pore formation in target liposomes by viral fusion proteins. Methods Enzymol 2003;372:408-18.
19. Ramani K, Bora RS, Kumar M, Tyagi SK, Sarkar DP. Novel gene delivery to liver cells using engineered virosomes. FEBS Lett 1997;404(2-3):164-8.
20. Homhuan A, Prakongpan S, Poomvises P, Maas RA, Crommelin DJ, Kersten GF, et al. Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity. Eur J Pharm Sci 2004;22(5):459-68.
21. Reynolds DL, Maraqa AD. Protective immunity against Newcastle disease: the role of antibodies specific to Newcastle disease virus polypeptides. Avian Dis 2000;44(1):138-44.
22. Deshmukh DR, Pomeroy BS. Ultraviolet inactivation and photoreactivation of avian viruses. Avian Dis 1969;13(3):596-602.
23. Markgraf K, Muller K, Ponimaskin EG, Rudolph M, Schmidt MF, Herrmann A. Lipid composition of virosomes modulates their fusion efficiency with cryop-reserved bull sperm cells. Cloning 2001;3(1):11-21.
24. Gomis S, Babiuk L, Godson DL, Allan B, Thrush T, Townsend H, et al. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun 2003;71(2):857-63.
25. Singh R, Verma PC, Singh S. Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease. Trop Anim Health Prod 2010;42:465-71.
26. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005;23(10):1232-41.
27. Mallick AI, Singha H, Chaudhuri P, Nadeem A, Khan SA, Dar KA, et al. Lipo-somised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection. Vaccine 2007;25(18):3692-704.
28. Haghighi HR, Read LR, Haeryfar SM, Behboudi S, Sharif S. Identification of adual -specific T cell epitope of the hemagglutinin antigen of an H5 avian influenza virus in chickens. PLoS One 2009;4(11):e7772.
29. Abdul-Careem MF, Hunter BD, Sarson AJ, Mayameei A, Zhou H, Sharif S. Marek's disease virus-induced transient paralysis is associated with cytokine gene expression in the nervous system. Viral Immunol 2006;19(2): 167-76.
30. Sarson AJ, Parvizi P, Lepp D, Quinton M, Sharif S. Transcriptional analysis of host responses to Marek's disease virus infection in genetically resistant and susceptible chickens. Anim Genet 2008;39(3):232-40.
31. de Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004;103(1-2): 139-45.
32. Wiedermann G,Kundi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop 1998;69(2):121-5.
33. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, et al. Immuno stimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for Leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999;96(12): 6970-5.
34. Stacey KJ, Blackwell JM. Immuno stimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999;67(8):3719-26.
35. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164(2):944-53.
36. Freidag BL, Melton GB, Collins F, Klinman DM, Cheever A, Stobie L, et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun 2000;68(5):2948-53.
37. Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 2002;14(4):411-9.
38. Wilson KD, Raney SG, Sekirov L, Chikh G, deJong SD, Cullis PR, et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol 2007;7(8):1064-75.
39. Radosevic K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 2008;26(29-30):3640-6.
40. Zhang L, Zhang M, Li J, Cao T, Tian X, Zhou F. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo. Res Vet Sci 2008;85(3):495-502.
41. Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, Parato KG, et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Ther Vaccines 2008; 6:4.
42. van Slooten ML, Storm G, Zoephel A, Kupcu Z, Boerman O, Crommelin DJ, et al. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res 2000;17(1):42-8.
43. van Slooten ML, Hayon I, Babai I, Zakay-Rones Z, Wagner E, Storm G, et al. Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines. Biochim Biophys Acta 2001;1531(1-2): 99-110.
44. Schulman JL, Kilbourne ED. Independent variation in nature of haemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of haemag-glutinin antigen of Hong Kong-68 virus. Proc Natl Acad Sci 1969;63(2): 326-33.
45. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A (H3N2) drifted influenza viruses. Vaccine 2008;26(12):1525-9.
46. Air GM. Sequence relationships among the hemagglutinin genesof12subtypes of influenza A virus. Proc Natl Acad Sci 1981;78(12):7639-43.
47. Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Underdown B, et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 1998;177:1266-74.
48. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes in influenza A virus knowledge and opportunities. Proc Natl Acad Sci 2007;104(1):247-51.
49. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG. Effector CD4+ andCD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997;159:105-17.
50. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 2000;18(14):1327-33.
51. Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A, et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 2005;17(6):695-704.
52. Faulkner L, Buchan G, Slobbe L, Lockhart E, Wales J, Wilson M, et al. Influenza haemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. Vaccine 2003;21(9-10):932-9.
53. Wilson KD, de Jong SD, Kazem M, Lall R, Hope MJ, Cullis PR, et al. The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine. J Gene Med 2009;11(1):14-25.
54. Koppenhagen FJ, Visser AJ, Herron JN, Storm G, Crommelin DJ. Interaction of recombinant interleukin-2 with liposomal bilayers. J Pharm Sci 1998;87(6):707-14.